Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance

Hepatology Research

Volumn 46, Issue 12, 2016, Pages 1264-1274

  Ferroudj, Sana ^a,b,c   Yildiz, Gokhan ^a,d   Bouras, Mourad ^a,e   Iscan, Evin ^c   Ekin, Umut ^c   Ozturk, Mehmet ^a,c  

^a UNIV GRENOBLE ALPES   (France)

^b FERHAT ABBAS UNIVERSITY   (Algeria)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d ERZINCAN UNIVERSITY   (Turkey)

^e UNIVERSITY OF BATNA   (Algeria)

Author keywords

BRCA1; chemosensitization; DSB DNA repair; Fanconi anemia; hepatocellular cancer; interstrand cross linker drugs

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; MELPHALAN; MITOMYCIN; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG RESISTANCE; FANCONI ANEMIA; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84963533287     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12675     Document Type: Article

References (30)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–76.
2. Inaba M, Sakurai Y. Role of DNA repair in natural resistance of rat ascites hepatomas to nitrogen mustard. Gann 1977; 68: 15–9.
3. Barranco SC, Haenelt BR, Gee EL. Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res 1978; 38: 656–60.
4. Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013; 19: 6144–55.
5. Breier A, Gibalova L, Seres M, Barancik M, Sulova Z. New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 2013; 13: 159–70.
6. Chenivesse X, Franco D, Bréchot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol 1993; 18: 168–72.
7. Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci 1991; 98: 317–22.
8. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langouet S. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol 2005; 43: 288–93.
9. Wang H, Zuo B, Wang H et al. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012; 422: 103–8.
10. Fujimaki S, Matsuda Y, Wakai T et al. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett 2012; 319: 98–108.
11. Yildiz G, Arslan-Ergul A, Bagislar S et al. Genome-wide transcriptional reorganization associated with senescence-to- immortality switch during human hepatocellular carcinogenesis. PLoS One 2013; 8: e64016.
12. Wurmbach E, Chen YB, Khitrov G et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938–47.
13. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5: e13984.
14. Shannon P, Markiel A, Ozier O et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498–504.
15. Sayan BS, Ince G, Sayan AE, Ozturk M. NAPO as a novel marker for apoptosis. J Cell Biol 2001; 155: 719–24.
16. Atalay A, Crook T, Ozturk M, Yulug IG. Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res Commun 2002; 299: 839–46.
17. Yuzugullu H, Benhaj K, Ozturk N et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009; 8: 90.
18. Fuchs BC, Fuji T, Dorfman JD et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008; 68: 2391–9.
19. Anastassiou D, Rumjantseva V, Cheng W et al. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 2011; 11: 529.
20. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001; 61: 4842–50.
21. Palagyi A, Neveling K, Plinninger U et al. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer 2010; 9: 127.
22. Wang CL, Gautier J. The Fanconi anemia pathway and ICL repair: implications for cancer therapy. Crit Rev Biochem Mol Biol 2010; 45: 424–39.
23. Yarde ND, Oliveira V, Mathews L et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 2009; 69: 9367–75.
24. Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740–6.
25. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–73.
26. Dave B, Mittal V, Tan MN, Chang CJ. Epithelial–mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012; 14: 202.1–5.
27. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443–9.
28. Heinrich MC, Hoatlin ME, Zigler AJ et al. DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998; 91: 275–87.
29. Yun J, Zhong Q, Kwak JY, Lee WH. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene 2005; 24: 4009–16.
30. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762–73.